nect Biopharma (US:CNTB) Globenewswire·2025-05-28 13:00Company Overview - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD) [3] - The company is headquartered in San Diego, California and is advancing rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody [3] - Rademikibart targets acute exacerbations in asthma and COPD, addressing significant unmet needs among approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually [3] Clinical Development - In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, showing clinically meaningful reductions in exacerbations and rapid improvements in forced expiratory volume in one second (FEV1) [3] - Improvements in FEV1 were observed within one week, and in most cases, within 24 hours via home spirometry [3] Upcoming Events - Company management will participate in the Noble Capital Markets Virtual Conference on June 4, 2025, at 9:00 a.m. ET [1] - The Jefferies Healthcare Conference will take place on June 5, 2025, at 7:35 a.m. ET, with a live webcast available on the company's website [2]